Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 30, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present at Jefferies 2018 Healthcare Conference

NEWTON, Mass., May 30, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing...
May 08, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update

-- Initiated Phase 3 Study URIROX-1™ and Phase 2 Study 206 for ALLN-177 in Patients with Severe Hyperoxaluria -- -- Reiterates Guidance for Key Objectives Across Portfolio-- NEWTON, Mass., May 08,...
March 27, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

-- Initiated URIROX-1™, First Phase 3 Trial of ALLN-177 in Enteric Hyperoxaluria; Topline Data Expected in Second Half of 2019 – -- Initiated Phase 2 Trial of ALLN-177 for Patients with Primary...
March 07, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present at Cowen and Company 38th Annual Health Care Conference

NEWTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, clinical biopharmaceutical company dedicated to developing and commercializing...
March 06, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Initiates First Phase 3 Trial for ALLN-177 in Patients with Enteric Hyperoxaluria

URIROX-1TM is the Largest Controlled Trial of a Novel Therapeutic for this Underserved Patient Population - Topline Data Expected in Second Half of 2019 -ALLN-177 has Potential to be the First...
December 14, 2017 07:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update

-- Successfully Completed Initial Public Offering, Raising $74.9 Million in Gross Proceeds -- Presented Final Results from Phase 2 Trials of ALLN-177 in Secondary Hyperoxaluria at ASN Kidney Week...
November 01, 2017 21:03 ET | Source: ALLENA PHARMACEUTICALS, INC.

Allena Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering

NEWTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme...